ALX Oncology

ALXO

Capitalización de mercado USD 147 M

Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.

Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their sector so far this year.

– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – – Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept – – Strong enrollment momentum in Phase 1 clinical trial of ALX2004 in EGFR expressing solid tumors with initial safety data on-track for 2H 2026 – – Strengthened leadership team with the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 500,000 shares of ALX Oncology's common stock to Michael Listgarten, General Counsel, on June 29, 2026 in connection with the commencement of his employment. Mr. Listgarten's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Listgarten to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif.

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York.

Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript

ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continued good execution,” including a February financing and the addition of Jeff Knight as chief development and chief operating officer.